Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yujia Song

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Nature Communications|May 18, 2026
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope studyJunzhe Yi, Jiongliang Wang, Yimin Zhang, et al.
Hepatology International|February 11, 2025
Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombusSuixing Zhong, Junzhe Yi, Song Chen, et al.
Haematologica|February 22, 2024
Enhancement of PRMT6 binding to a novel germline <i>GATA1</i> mutation associated with congenital anemiaYingsi Lu, Qingqing Zhu, Yun Wang, et al.
Journal of Medicinal Chemistry|March 13, 2026
Chemical Space Navigation of Nitidine Leads to the Discovery of a Novel PD-L1 Degradation Agent by Targeting CSN5 for Enhanced Antitumor ImmunityQun Wang, Mengmeng Guo, Yujia Song, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Nature Communications|May 18, 2026
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope studyJunzhe Yi, Jiongliang Wang, Yimin Zhang, et al.
Hepatology International|February 11, 2025
Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombusSuixing Zhong, Junzhe Yi, Song Chen, et al.
Haematologica|February 22, 2024
Enhancement of PRMT6 binding to a novel germline <i>GATA1</i> mutation associated with congenital anemiaYingsi Lu, Qingqing Zhu, Yun Wang, et al.
Journal of Medicinal Chemistry|March 13, 2026
Chemical Space Navigation of Nitidine Leads to the Discovery of a Novel PD-L1 Degradation Agent by Targeting CSN5 for Enhanced Antitumor ImmunityQun Wang, Mengmeng Guo, Yujia Song, et al.
Pageof 7